-
2024-516725-31-00
9
2016-04-14
advanced and metastatic
-
2023-506027-29-00
5
2014-10-01
Children, adolescents and adults with newly diagnosed diffuse intrinsi
-
2024-516358-23-00
5
2013-06-24
Gastric adenocarcinoma
-
2024-519773-19-00
5
2025-07-31
Gastroesophageal Junction Adenocarcinoma
-
2024-517817-34-00
9
2025-06-18
Gastric Cancer
-
2024-517818-15-00
9
2025-06-06
Non-Small Cell Lung Cancer
-
2024-513307-13-00
4
2025-05-26
Advanced/metastatic solid tumors including gynecological
cancers (endo
-
2024-512925-95-00
5
2025-05-16
Advanced/Metastatic Breast Cancer
-
2024-517114-15-00
7
2025-03-07
newly diagnosed gliblastoma
-
2024-512998-27-00
5
2025-02-21
Non-Small Cell Lung Cancer
-
2024-510719-31-00
5
2025-01-24
Moderate to Severe Vasomotor Symptoms (VMS)
-
2024-511957-23-00
5
2025-01-03
Recurrent or Persistent Endometrial Cancer
-
2023-505617-24-00
4
2024-11-05
Recurrent Ovarian Cancer with High Folate Receptor-Alpha Expression
-
2023-509716-29-00
9
2024-09-23
Solid Tumors, Colorectal Cancer and Breast Cancer
-
2023-508219-21-00
5
2024-09-12
BTC - Biliary Tract Cancer
-
2023-505594-32-00
1
2024-02-20
Advanced solid tumors
-
2023-509568-81-00
1
2023-07-27
Advanced Breast Cancer and Other Solid Tumors
-
2023-509825-38-00
5
2022-12-01
Metastatic Non–Small Cell Lung Cancer
-
2024-514480-26-00
4
2022-10-12
Post-menopausal women with localized luminal A breast cancer and consi
-
2024-517024-20-00
9
2022-09-27
Metastatic colorectal cancer patients
-
2023-504996-26-00
5
2022-07-21
Metastatic Castration Resistant Prostate Cancer (mCRPC)
-
2024-512127-36-00
9
2022-03-31
Non-Small Cell Lung Cancer
-
2024-512148-50-00
5
2022-03-03
Non-small cell lung cancer
-
2024-515617-18-00
1
2022-02-14
Advanced clear cell renal cell carcinoma (ccRCC), non-clear cell renal